Development of acute nonlymphocytic leukaemia (ANLL) in myelomatosis.
On the basis of the literature, so-called secondary acute nonlymphocytic leukaemia (S-ANLL) in myelomatosis is reviewed. Using the banding technique, cytogenetic changes including hypodiploidy and partially or totally missing chromosomes # 5 and # 7 are recorded. The findings are in accordance with the cytogenetic changes seen in S-ANLL in other malignancies which have been treated with cytostatics, especially alkylating agents. So, S-ANLL in myelomatosis seems to be a result of treatment with cytostatics, though a causal relationship has to be documented.
D000208:Acute Disease; D000477:Alkylating Agents / Q000009:adverse effects; D006801:Humans; D007938:Leukemia / Q000139:chemically induced / Q000209:etiology* / Q000235:genetics; D009101:Multiple Myeloma / Q000150:complications*; D009381:Neoplasms, Radiation-Induced
D000477:Alkylating Agents